Home New England Boston, MA Elicio Therapeutics COMPANY
Clinical Phase 2
1 open job · last seen Oct 23, 2026 · 4 sources
Keywords: oncology vaccine infectious disease cancer Pancreatic Ductal Adenocarcinoma KRAS G12D KRAS G12R NRAS G12D NRAS G12R Colorectal Cancer KRAS G12V KRAS G12A KRAS G12C KRAS G12S KRAS G13D NRAS G12V NRAS G12C NRAS G12S NRAS G12A NRAS G13D Minimal Residual Disease Non-small Cell Lung Cancer Ovarian Cancer Cholangiocarcinoma Bile Duct Cancer Gallbladder Carcinoma ELI-002 7P ELI-002 2P Show all 28 keywords
Location: Boston, MA · source · Oct 15, 2026
Profile checked Oct 10, 2026
At a glance HQ Boston, MA source Region New England Stage Clinical Phase 2 Latest trial Phase 1/Phase 2: A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors (Apr 14, 2023) source Raises and deals from press releases Raises announced in these releases: $10M disclosed.
From the company’s own releases; this list is partial. All raises and deals
Timeline Jul 1, 2026 Raise Follow-on offering — Registered direct: $15M (total, as published), announced Jul 1, 2026. Source: SEC filing. source ↗ Jun 4, 2025 Raise Private placement: $10M (total, as published), announced Jun 4, 2025. Source: SEC filing. source ↗ Jun 4, 2025 Raise Undisclosed round · $10M source ↗ Apr 14, 2023 Trial start Phase 1/Phase 2: A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors source ↗ Oct 4, 2021 Trial start Phase 1: A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors source ↗ Funding Raised: $25.0M. Last 2 years.
Jul 1, 2026 Follow-on offering — Registered direct: $15M (total, as published), announced Jul 1, 2026. Source: SEC filing. source ↗ Jun 4, 2025 Private placement: $10M (total, as published), announced Jun 4, 2025. Source: SEC filing. source ↗ Clinical trials (lead sponsor) 3 Record Title Phase Status Start Primary completion NCT05726864 A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors Phase 1/Phase 2 Active, not recruiting Apr 14, 2023 Apr 20, 2026 (actual) NCT07083479 Expanded Access Protocol of ELI-002-102 in Subjects With KRAS/NRAS Mutated Pancreatic Ductal Adenocarcinoma Not listed No longer available Not listed Not listed NCT04853017 A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors Phase 1 Completed Oct 4, 2021 Jan 26, 2023 (actual)
Open jobs 1 Title Location (from posting, not HQ) Employer posted First seen Level Accounting Manager (Contractor) Boston, Massachusetts, United States Not stated Oct 14, 2026 Mid Description
Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.
Connect See your connections at Elicio Therapeutics on LinkedIn (search by name, results not checked) LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.
LinkedIn page linked from the company's own site: source · seen 2026-10-18
